<SEC-DOCUMENT>0001193125-20-105808.txt : 20200414
<SEC-HEADER>0001193125-20-105808.hdr.sgml : 20200414
<ACCEPTANCE-DATETIME>20200414073104
ACCESSION NUMBER:		0001193125-20-105808
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20200413
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Termination of a Material Definitive Agreement
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200414
DATE AS OF CHANGE:		20200414

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MEI Pharma, Inc.
		CENTRAL INDEX KEY:			0001262104
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				510407811
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-50484
		FILM NUMBER:		20790062

	BUSINESS ADDRESS:	
		STREET 1:		3611 VALLEY CENTER DRIVE
		STREET 2:		SUITE 500
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
		BUSINESS PHONE:		858-792-6300

	MAIL ADDRESS:	
		STREET 1:		3611 VALLEY CENTER DRIVE
		STREET 2:		SUITE 500
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MARSHALL EDWARDS INC
		DATE OF NAME CHANGE:	20030902
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d891047d8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML><HEAD>
<TITLE>8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 8-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant
to Section&nbsp;13 or 15(d) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of Earliest Event Reported): April&nbsp;13, 2020 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>MEI Pharma, Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact
name of registrant as specified in its charter)</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>000-50484</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>51-0407811</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>incorporation or organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>3611 Valley Centre Drive, Suite 500, San Diego, California 92130 </B> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices) (Zip Code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code: (858)&nbsp;369-7100 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I></I>Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (<I>see</I> General Instruction A.2. below):<I> </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&nbsp;12(b) of the Act: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title of each class</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Trading</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Symbol</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Name of each exchange</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>on which registered</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Common stock, $0.00000002 par value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>MEIP</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>The NASDAQ Stock Market LLC</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of
1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter). </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Emerging growth company </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended
transition period for complying with any new or revised financial accounting standards provided pursuant to section 13(a) of the Exchange Act. </P></TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item&nbsp;1.01</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Entry into a Material Definitive Agreement. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>License, Development and Commercialization Agreement </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
April&nbsp;13, 2020, MEI Pharma, Inc. (the &#147;Company&#148;) entered into a License, Development and Commercialization Agreement (the &#147;Agreement&#148;) with Kyowa Kirin Co., Ltd. (formerly known as Kyowa Hakko Kirin Co., Ltd.), a Japanese
corporation having an office at 1-9-2 Otemachi, Chiyoda-ku, Tokyo 100-0004, Japan (&#147;KKC&#148;), effective as of April&nbsp;13, 2020 (the &#147;Effective Date&#148;). Pursuant to the terms of the Agreement, the Company and KKC have agreed to
terminate the License, Development and Commercialization Agreement dated October&nbsp;31, 2018 (the &#147;JP Agreement&#148;) and to expand the scope of the JP Agreement to collaborate on the development, manufacturing and commercialization of
ME-401 (the &#147;Collaboration&#148;) globally in accordance with the Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Agreement has a term (the &#147;Term&#148;) commencing on the
Effective Date and continuing in full force and effect, on a country-by-country and product-by-product basis, until the latest of the expiration of the applicable patent, the expiration of regulatory exclusivity or ten years after the date of first
commercial sale for such product in such country. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company grants to KKC a co-exclusive, sublicensable, payment-bearing license under certain patents
and know-how controlled by the Company to develop and commercialize ME-401 and any pharmaceutical product containing ME-401 for all human indications in the U.S., and an exclusive (subject to certain retained rights to perform obligations under the
Agreement), sublicensable, payment-bearing, license under certain patents and know-how controlled by the Company to develop and commercialize ME-401 and any pharmaceutical product containing ME-401 for all human indications in countries outside of
the United States (the &#147;Ex-US&#148;). KKC grants to the Company a co-exclusive, sublicensable, license under certain patents and know-how controlled by KKC to develop and commercialize ME-401 for all human indications in the U.S., and a
co-exclusive, sublicensable, royalty-free, fully paid license under certain patents and know-how controlled by KKC to perform the Company&#146;s obligations in the Ex-US under the Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">KKC will be responsible for the development and commercialization of ME-401 in the EX-US and, subject to certain exceptions, will be solely responsible for
all costs related thereto. The Company and KKC will co-develop and co-promote ME-401 in the U.S., with the Company booking all revenue from U.S. sales. The Company and KKC will share U.S. profits and costs (including development costs) on a 50-50
basis. The Company will also provide to KKC certain drug supplies necessary for the development and commercialization of ME-401 in the Ex-US pursuant to supply agreements to be entered into on customary terms, with the understanding that KKC will
assume responsibility for manufacturing for the Ex-US as soon as practicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms of the Agreement, KKC will pay the Company an initial
payment of $100 million within 30 days after the receipt of an invoice from the Company. The Company may earn up to approximately $582.5 million in potential development and commercialization milestone payments, plus royalties on net sales of ME-401
in the Ex-US, which are tiered beginning in the teens. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Collaboration will be managed by a joint steering committee in which both parties are
represented equally, which will serve as a forum for the sharing of information and facilitating communications between the parties regarding development and commercialization activities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Agreement, each party will maintain ownership of its own technology and intellectual property existing prior to, or outside of, the Collaboration,
each party will be the exclusive owner of any and all inventions it solely develops under the Agreement, and the parties shall jointly own any and all inventions developed by the parties jointly under the Agreement. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">KKC has the right to terminate the Agreement for convenience upon prior written notice. If either party
materially breaches the Agreement, the non-breaching party may terminate the Agreement if the breach is not cured. If either party files or institutes bankruptcy, reorganization, liquidation or receivership proceedings, or assigns a substantial
portion of its assets for the benefit of creditors, the other party may terminate the Agreement, provided, that, if such proceeding is involuntary, the other party may terminate the Agreement only if such proceeding is not dismissed. The Company may
also terminate the Agreement in the event that KKC challenges any of the Company&#146;s licensed patents. The Agreement shall also automatically terminate if KKC fails to make the upfront payment and is terminable by the Company if KKC fails to
comply with certain data privacy and security obligations. Each party may terminate the Agreement in connection with an event of force majeure under certain circumstances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If KKC terminates the Agreement due to an uncured material breach of the Agreement by the Company (or due to the Company&#146;s filing or institution of
bankruptcy, reorganization, liquidation or receivership proceedings, or the Company&#146;s assignment of a substantial portion of its assets for the benefit of creditors), all licenses granted to KKC will immediately terminate and KKC shall cease
developing and commercializing ME-401. In the event of such termination, KKC shall either withdraw all regulatory approvals for ME-401 or, with the Company&#146;s prior written consent, assign such regulatory approvals and related materials to the
Company. If KKC terminates the Agreement for convenience or in connection with a force majeure event, or if the Company terminates the Agreement due to KKC&#146;s uncured material breach of the Agreement, KKC&#146;s filing or institution of
bankruptcy, reorganization, liquidation or receivership proceedings, or KKC&#146;s assignment of a substantial portion of its assets for the benefit of creditors, KKC&#146;s challenge of any of the Company&#146;s licensed patents, KKC&#146;s failure
to make the upfront payment, KKC&#146;s failure to comply with certain data privacy and security obligations, or in connection with a force majeure event, in each such case, all licenses granted to KKC will immediately terminate, KKC shall cease
developing and commercializing ME-401, assign all regulatory approvals for ME-401 and related materials to the Company, and assign, or grant the Company an exclusive, royalty-bearing, worldwide, perpetual and irrevocable license to, certain data and
technology developed by KKC, for the development and commercialization of ME-401 by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing description of the material terms of the
Agreement is qualified in its entirety by reference to the complete text of the Agreement, which the Company intends to file, with confidential terms redacted, with the Securities and Exchange Commission as an exhibit to the Company&#146;s Annual
Report on Form 10-K for the year ending June&nbsp;30, 2020. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item&nbsp;1.02</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Termination of a Material Definitive Agreement. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&nbsp;13, 2020, the Company and KKC agreed to terminate the License, Development and Commercialization Agreement (JP Agreement), dated October&nbsp;31,
2018. Pursuant to the terms of the Agreement, the Company and KKC had agreed to collaborate on the development, manufacturing and commercialization of ME-401 in Japan. The JP Agreement was replaced with a broader License, Development and
Commercialization Agreement between the two parties, entered into on April&nbsp;13, 2020. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item&nbsp;8.01</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Other Events. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&nbsp;14, 2020, the Company issued a press release regarding the Agreement, a copy of which is attached as Exhibit 99.1 to this Current Report on Form
8-K and incorporated herein by reference. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Supplemental Risk Factor </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In light of recent developments relating to the COVID-19 global pandemic, the Company is supplementing the risk factors previously disclosed in Item&nbsp;1A.
of its Annual Report on Form 10-K for the year ended June&nbsp;30, 2019, as filed with the Securities and Exchange Commission on August&nbsp;28, 2019, to include the following risk factor under the heading &#147;Risks Related to our Business and
Industry&#148;: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The outbreak of the novel coronavirus disease, COVID-19, or other pandemic, epidemic or outbreak of an infectious disease may
materially and adversely impact our business, including our preclinical studies and clinical trials. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December 2019, the novel coronavirus
disease, COVID-19, was identified in Wuhan, China. This virus has been declared a pandemic and has spread to multiple global regions. The outbreak and government measures taken in response have also had a significant impact, both direct and
indirect, on businesses and commerce, as worker shortages have occurred; supply chains have been disrupted; facilities and production have been suspended; and demand for certain goods and services, such as medical services and supplies, has spiked,
while demand for other goods and services, such as travel, has fallen. In response to the COVID-19 outbreak, &#147;shelter in place&#148; orders and other public health guidance measures have been implemented across much of the United States, Europe
and Asia, including in the locations of our offices, clinical trial sites, key vendors and partners. Our clinical development program timelines may be negatively affected by COVID-19, which could materially and adversely affect our business,
financial condition and results of operations. Further, due to &#147;shelter in place&#148; orders and other public health guidance measures, we have implemented a work-from-home policy for all staff members excluding those necessary to maintain
minimum basic operations. Our increased reliance on personnel working from home may negatively impact productivity, or disrupt, delay or otherwise adversely impact our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result of the COVID-19 outbreak, or similar pandemics, and related &#147;shelter in place&#148; orders and other public health guidance measures, we have
and may in the future experience disruptions that could materially and adversely impact our clinical trials, business, financial condition and results of operations. Potential disruptions include but are not limited to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays or difficulties in enrolling patients in our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays or difficulties in initiating or expanding clinical trials, including delays or difficulties with clinical
site initiation and recruiting clinical site investigators and clinical site staff; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">increased rates of patients withdrawing from our clinical trials following enrollment as a result of contracting
COVID-19 or other health conditions or being forced to quarantine; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals
serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">interruption of key clinical trial activities, such as clinical trial site data monitoring, due to limitations on
travel imposed or recommended by federal or state governments, employers and others or interruption of clinical trial subject visits and study procedures, which may impact the integrity of subject data and clinical study endpoints;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">interruption or delays in the operations of the FDA or other regulatory authorities, which may impact review and
approval timelines; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays or disruptions in preclinical experiments and investigational new drug application-enabling studies due to
restrictions of on-site staff and unforeseen circumstances at contract research organizations and vendors; </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">interruption of, or delays in receiving, supplies of our product candidates from our contract manufacturing
organizations due to staffing shortages, production slowdowns or stoppages and disruptions in delivery systems; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">limitations on our ability to recruit and hire key personnel due to our inability to meet with candidates because
of travel restrictions and &#147;shelter in place&#148; orders; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">limitations on employee resources that would otherwise be focused on the conduct of our preclinical studies and
clinical trials, including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">interruption or delays to our sourced discovery and clinical activities. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The COVID-19 pandemic continues to rapidly evolve. The extent to which the outbreak impacts our business, preclinical studies and clinical trials will depend
on future developments, which are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of the disease, the duration of the pandemic, travel restrictions and social distancing in the United States and other
countries, business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain and treat the disease. If we or any of the third parties with whom we engage were to experience shutdowns
or other business disruptions, our ability to conduct our business in the manner and on the timelines presently planned could be materially and negatively impacted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the trading prices for our common stock and other biopharmaceutical companies have been highly volatile as a result of the COVID-19 pandemic. As
a result, we may face difficulties raising capital through sales of our common stock or such sales may be on unfavorable terms. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item&nbsp;9.01</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Financial Statements and Exhibits. </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Exhibits </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="88%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>Exhibit&nbsp;99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d891047dex991.htm">Press release of MEI Pharma, Inc. dated April&nbsp;13, 2020 relating to License, Development and Commercialization Agreement with Kyowa Kirin Co., Ltd. </A></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Signatures </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">MEI PHARMA, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Daniel P. Gold</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Daniel P. Gold</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Chief Executive
Officer</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: April&nbsp;14, 2020 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d891047dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">


<IMG SRC="g891047meilogo1.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">


<IMG SRC="g891047kyowakirinlogo1.jpg" ALT="LOGO">
</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MEI Pharma and Kyowa Kirin Announce Global License, Development and Commercialization Agreement for <FONT
STYLE="white-space:nowrap">ME-401</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>MEI Pharma and Kyowa Kirin will <FONT STYLE="white-space:nowrap">co-develop</FONT> and <FONT
STYLE="white-space:nowrap">co-promote</FONT> <FONT STYLE="white-space:nowrap">ME-401</FONT> in the U.S.; MEI to book U.S. sales on <FONT STYLE="white-space:nowrap">50-50</FONT> profit and cost sharing</I> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Kyowa Kirin obtains exclusive commercialization rights <FONT STYLE="white-space:nowrap">ex-U.S.;</FONT> MEI to
receive escalating tiered royalty payments on <FONT STYLE="white-space:nowrap">ex-U.S.</FONT> sales </I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>MEI to receive $100</I><I></I><I>&nbsp;million in an upfront cash payment and is eligible to receive up to an
additional $582.5</I><I></I><I>&nbsp;million based on the achievement of specified development, regulatory and commercial milestones</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>MEI to host conference call on April</I><I></I><I>&nbsp;14 at 8:00 a.m. ET </I> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SAN DIEGO, and TOKYO, April&nbsp;14, 2020 &#150; MEI Pharma, Inc. (NASDAQ: MEIP) and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151) today jointly announced
that the companies have entered into a global license, development and commercialization agreement to further develop and commercialize MEI&#146;s <FONT STYLE="white-space:nowrap">ME-401,</FONT> an oral, once-daily, investigational drug-candidate,
selective for phosphatidylinositol <FONT STYLE="white-space:nowrap">3-kinase</FONT> delta (PI3K<FONT STYLE="FONT-FAMILY:SYMBOL">&#100;</FONT>), in clinical development for the treatment
<FONT STYLE="white-space:nowrap">of&nbsp;B-cell&nbsp;malignancies.</FONT> MEI and Kyowa Kirin will <FONT STYLE="white-space:nowrap">co-develop</FONT> and <FONT STYLE="white-space:nowrap">co-promote</FONT>
<FONT STYLE="white-space:nowrap">ME-401</FONT> in the U.S., with MEI booking all revenue from U.S. sales. Kyowa Kirin has exclusive commercialization rights outside of the U.S. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">ME-401</FONT> is being studied in the ongoing Phase 2 TIDAL clinical trial evaluating patients with relapsed or refractory
follicular lymphoma which, subject to results, may support an accelerated approval of a marketing application with the U.S. Food and Drug Administration (FDA). An ongoing Phase 1b study is evaluating <FONT STYLE="white-space:nowrap">ME-401</FONT> as
a monotherapy and in combination with rituximab (Rituxan<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>) or zanubrutinib (Brukinsa<SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP>) in patients with
<FONT STYLE="white-space:nowrap">B-cell</FONT> malignancies. Also, a Phase 1 study was initiated in 2019 evaluating <FONT STYLE="white-space:nowrap">ME-401</FONT> as a monotherapy in patients with indolent
<FONT STYLE="white-space:nowrap">B-cell</FONT> malignancy in Japan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;This global partnership with Kyowa Kirin is a key step to achieving our goal of
broadly developing and commercializing <FONT STYLE="white-space:nowrap">ME-401,</FONT> optimizing the opportunity to benefit patients across multiple <FONT STYLE="white-space:nowrap">B-cell</FONT> malignancies inside and outside the U.S., and also
building value for our shareholders,&#148; said&nbsp;David M. Urso, J.D., chief operating officer&nbsp;&amp; general counsel of MEI Pharma. &#147;The decision to expand our alliance with Kyowa Kirin is based on the successful relationship we&#146;ve
built working together to date under our 2018 Japan license agreement, and the respect we have for Kyowa Kirin and their ability to jointly execute our shared vision of <FONT STYLE="white-space:nowrap">ME-401</FONT> in the U.S. and around the
world.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;I am delighted to expand our agreement with MEI Pharma for the development and commercialization of
<FONT STYLE="white-space:nowrap">ME-401</FONT> all over the world,&#148; said Tomohiro Sudo, Executive Officer, Director of Strategic Product Planning Department for Kyowa Kirin. &#147;We believe that <FONT STYLE="white-space:nowrap">ME-401</FONT>
may be an important new treatment option for patients and further enhances our global oncology pipeline.&#148; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About the Global License, Development and Commercialization Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms of the agreement, which substantially retains and consolidates the terms of the 2018 license agreement between MEI and Kyowa Kirin to develop
and commercialize <FONT STYLE="white-space:nowrap">ME-401</FONT> in Japan, MEI will receive a $100&nbsp;million upfront payment from Kyowa Kirin. MEI is also eligible to receive up to $582.5&nbsp;million in additional payments from Kyowa Kirin
depending on the achievement of certain U.S. and <FONT STYLE="white-space:nowrap">ex-U.S.</FONT> development, regulatory and commercial milestones. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If
approved by FDA in the U.S., MEI and Kyowa Kirin will <FONT STYLE="white-space:nowrap">co-promote</FONT> <FONT STYLE="white-space:nowrap">ME-401,</FONT> with MEI booking all revenue from sales. MEI and Kyowa Kirin will share U.S. profits and costs
(including development costs) on a <FONT STYLE="white-space:nowrap">50-50</FONT> basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Outside the U.S., Kyowa Kirin will have exclusive
commercialization rights, lead commercialization and book all revenues from sales of <FONT STYLE="white-space:nowrap">ME-401.</FONT> Kyowa Kirin will pay MEI escalating tiered royalties on <FONT STYLE="white-space:nowrap">ex-U.S.</FONT> sales
starting in the teens. Kyowa Kirin will be responsible for all incremental <FONT STYLE="white-space:nowrap">ex-U.S.</FONT> clinical development costs and all <FONT STYLE="white-space:nowrap">ex-U.S.</FONT> regulatory, CMC and commercial costs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The companies have agreed to a development plan designed to broadly evaluate <FONT STYLE="white-space:nowrap">ME-401</FONT> in patients with various <FONT
STYLE="white-space:nowrap">B-cell</FONT> malignancies, including in combination with other agents. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conference Call&nbsp;&amp; Webcast Information
(Conducted by MEI) </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">When:&nbsp;April 14, 2020,&nbsp;8:00 a.m. ET </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Dial-in:</FONT>
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-877-879-1183</FONT></FONT></FONT> (International Toll: <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">1-412-902-6703)</FONT></FONT></FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Conference ID: 0809665 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Please join the conference call at least 10 minutes early to register. You can access the live webcast under the investor relations section of MEI&#146;s
website at: <U>www.meipharma.com</U>. A replay of the conference call will be archived under <U>events and webcasts</U> for at least 30 days after the call. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About <FONT STYLE="white-space:nowrap">ME-401</FONT> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">MEI-401</FONT> is an investigational treatment and not approved by the U.S. Food and Drug Administration (FDA) or other Health Authorities. Clinical development of <FONT STYLE="white-space:nowrap">ME-401</FONT> as an oral,
once-daily, selective PI3K<FONT STYLE="FONT-FAMILY:SYMBOL">&#100;</FONT> inhibitor for the treatment of <FONT STYLE="white-space:nowrap">B-cell</FONT> malignancies is ongoing. The U.S. FDA recently granted
<FONT STYLE="white-space:nowrap">ME-401</FONT> Fast Track designation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MEI is currently conducting two ongoing studies evaluating <FONT
STYLE="white-space:nowrap">ME-401.</FONT> The first is a Phase 2 clinical trial evaluating <FONT STYLE="white-space:nowrap">ME-401</FONT> as a monotherapy for the treatment of adults with relapsed or refractory follicular lymphoma after failure of
at least two prior systemic therapies including chemotherapy and an anti-CD20 antibody. Subject to the results, upon completion of the Phase&nbsp;2 clinical trial, <FONT STYLE="white-space:nowrap">ME-401</FONT> is planned to be submitted with the
FDA to support an accelerated approval of a marketing application under 21&nbsp;CFR Part&nbsp;314.500, Subpart&nbsp;H. The second study is a <FONT STYLE="white-space:nowrap">multi-arm,</FONT> open-label, Phase&nbsp;1b dose escalation and expansion
trial evaluating <FONT STYLE="white-space:nowrap">ME-401</FONT> as a monotherapy and in combination with other therapies or investigational agents in patients with relapsed or refractory <FONT STYLE="white-space:nowrap">B-cell</FONT> malignancies.
Additionally, a Phase 1 study was initiated by Kyowa Kirin in 2019 evaluating <FONT STYLE="white-space:nowrap">ME-401</FONT> as a monotherapy in patients with indolent <FONT STYLE="white-space:nowrap">B-cell</FONT> malignancy in Japan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About MEI Pharma </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MEI Pharma, Inc. (Nasdaq: MEIP) is a
late-stage pharmaceutical company focused on developing potential new therapies for cancer. Our portfolio of drug candidates contains four clinical-stage assets, </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
including one candidate in an ongoing global registration trial and another candidate in a Phase 2 clinical trial which may support an accelerated approval marketing application with the U.S.
Food and Drug Administration. Each of our pipeline candidates leverages a different mechanism of action with the objective of developing therapeutic options that are: (1)&nbsp;differentiated, (2) address unmet medical needs and (3)&nbsp;deliver
improved benefit to patients either as standalone treatments or in combination with other therapeutic options. For more information, please visit&nbsp;www.meipharma.com. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About&nbsp;Kyowa Kirin </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kyowa Kirin commits to innovative
drug discovery driven by <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">state-of-the-art</FONT></FONT></FONT> technologies. The company focuses on creating new value in the four therapeutic areas:
nephrology, oncology, immunology/allergy and neurology. Under the Kyowa Kirin brand, employees from 36 group companies across North America, EMEA and Asia/Oceania unite to champion the interests of patients and their caregivers by discovering
solutions to address unmet medical needs. You can learn more about the business of Kyowa Kirin at www.kyowakirin.com. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements
</B><I> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Under U.S. law, a new drug cannot be marketed until it has been investigated in clinical studies and approved by the FDA as being safe and
effective for the intended use. Statements included in this press release that are not historical in nature are &#147;forward-looking statements&#148; within the meaning of the &#147;safe harbor&#148; provisions of the Private Securities Litigation
Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management&#146;s current expectations and are subject to a number of risks and
uncertainties, including, but not limited to, our failure to successfully commercialize our product candidates; costs and delays in the development and/or FDA approval, or the failure to obtain such approval, of our product candidates; uncertainties
or differences in interpretation in clinical trial results; the impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on our industry and individual companies, including on our counterparties, the supply chain, the execution of our
clinical development programs, our access to financing and the allocation of government resources; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the
development, manufacture, commercialization, marketing, sales and distribution of any products; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual
property to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others; general economic conditions; the failure of any products to gain market acceptance; our inability to obtain any
additional required financing; technological changes; government regulation; changes in industry practice; and <FONT STYLE="white-space:nowrap">one-time</FONT> events. We do not intend to update any of these factors or to publicly announce the
results of any revisions to these forward-looking statements. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contacts for MEI Pharma, Inc.: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">David A. Walsey </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">VP of IR and Corporate Communications </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tel: <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">+1-858-369-7104</FONT></FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">investor@meipharma.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jason I. Spark </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Canale Communications for MEI </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tel: <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">+1-619-849-6005</FONT></FONT></FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">jason@canalecomm.com
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contacts for Kyowa Kirin Co., Ltd.: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Media </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Hiroki Nakamura </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">+81-3-5205-7205</FONT></FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Email: media@kyowakirin.com </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g891047kyowakirinlogo1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g891047kyowakirinlogo1.jpg
M_]C_X  02D9)1@ ! 0$!( $@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1"  _ 28# 2(  A$! Q$!_\0
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M#>FV^D:'HT MK2T@&%B0<]>K,22S,Q+,Q+$DDFORN_X+@?\ )Y.G?]BS;?\
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MP8^%EYKUOXS\.>(-0:W9M+TW3+^.[N-2F*_NU"QDD(21N<X55.2:^??VAO\
M@A;H?BGQ!<ZE\-?$B^$8;I_,.C7]NUW8VY.2PA<,)(T](SN"Y(7:H5!Y7HO_
M  05^(4E_B\\;>#+.W+?-)!:W$TC#_=.T9^IKY7 4^(,KHRP5&BIJ[M*ZTO\
MUIUU2UW['ZMQ!B/#WBG&T\[QF.E1E:*G3<6G*VR=HRL[>ZW%R325K/4^._A1
M\*=2^/OQ*T'P;:K->:CXLODLI6!^;;(<SRD_[,?F.3Q]T]*_2;_@O%\.UO\
M]GWP/XDAA+S>'/$'V&63_GC:W5O(&/XSP6H_&O:OV+/^"<7@G]C$W&IV,ESX
MB\77L)M[C7+Y0LB0D@F&"(?+#&2 6QEW(&YF"HJ]Q^U]^SA;?M8_L_ZYX&N;
MXZ7_ &H8)8;P0^=]FEAF25'V9&[#(.,CK75EO"=:AE->C4UJU$M+[..L5?:]
M]WL>3Q+XM8/'<6Y?C<+=87"R:YFFFU.T:DE%:VY4K*UW;5:V7XC7GQ%DN/V?
M=+\'>:S+:^*;S7&BP<(K65K!$V>G+&YX[8'J*^A?VKOABWAS_@ES^S5K<JKY
MGVV^A#=RNHK/?)]?DMEY]A7L1_X(#2_]%2;_ ,$8_P#CM?17Q]_X)XV_QM_8
MQ\ _"-?$CZ>W@&/3$M=5:S\YIC9V;6FXQ[QC>CO_ !'&>]>/@>%\Q]C75>GJ
MX*,5>.K4HOO_ '3[+/O%3AKZ[@)9?B+PA7E4J/DFK*4)Q;UBK_&]%=V/R/\
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1%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g891047meilogo1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g891047meilogo1.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" !Q '$# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]_***;(^T
M?7B@ :55-<K\3?B[X=^#^@2:CXBU2STNU4?+YC?O)3Z(O5C]*\3_ &P?V_-+
M^ ;W'A_P^L&M>,=O[Q2=UMIF<_-*1U<==@]1G%?!'C7XC:U\4?$LFL>(M2N=
M5U&0\R3-\L8]$7HH]A7YWQ5Q]A\MD\-A5[2JM_Y8^KZOR7S.'$8V--\L=6?7
MGQ1_X*EO)<RVO@?P[$T8X&HZNQ7)]5@7D_\  F7Z&O$O%'[6WQ*\;S,UYXTU
MBV1CQ#IKBPC0>@\K#?FQ/UKR6WGZ#\_>KMM/C;W%?AV<<6YSCF_;5Y)=HOE7
MX?J<,L54D]6=+>>*=4UJ3=?ZMK&H,>IN]1GN/_0W-$%SGI\O7FL>WFX_''UJ
MY!<9Z^O:OB<1%R;<]67&39LPSX]/RJW#<9/Z]*R89\?-WSQ_2K4,^?4G/2O-
MJ4[:,WC+L;,,V >_OBK<$V.O7J>/2LBVGX_GCM5R"7"X_'_/YUPU*6IT1D:L
M$F?3..>*M12\-TQC_P#5BLN&;!^]]*MQ29SVXK@J4SHC*YMY_P!JBJOF>QHJ
M?9FG,?HT[X7U^E?,7_!0C]M+_AGGPRGAOP[<1_\ "::U$65\;_[*@/!F89X<
M]$![\]J]I^-?Q:TWX&?"O6?%6K2!;/2+=IMI/,TF/D0>[,0/QK\=/'WQ+U3X
MM^.M4\3:W,TVJ:Q.9Y?2,?PQCV5<#\*_N/C;B&6!PZH8=_O)]>RZOU['EYEC
M/8QY([O\/,=]NEN[F:>::2>:8M++-*VYY7)R68]22><GGFK=M<8_^N:ZCX(?
MLM^._P!H30=4U3PKHZZA8Z1(;>:5YEA#S! YB3/WFVNI]MPKCYX)]-O;BUNH
M9[6[M9#%/!,I22%U)!5@>A%?@V*P&(C35:K!I2V;6C]&>"E-)3:T?4UH9\@?
MG5RWG]&8XSP1UK%M[@$CGCUKHO /@_5OB7XLL]#T.RFU#5+XD101^@Y+,>BJ
M.Y/%>.\+.I-4Z:;D]DMV=$7K9$EO<Y]\?G5ZWN.?Q]:U/BY\$O$WP"\0P:;X
MFL5M)KR+SH'CD$L4ZC@[6'<'J/>M/X4_L^^-OC+I\U[X;T.;4K.UD\MYS(L<
M>_NH+$9QWQTK.>3XR5=X14I>T7V;._W'1&,^;EMJ8MO/N/Z<U<@N,_Q5Z##^
MP]\557GPLW_@7%_C5B+]B;XI(H_XI=O_  +B_P :FIPEF^WU6I_X"SJC"?9G
M!V\_'S5;MY\8_7/?BM+XC_!;Q3\'$M&\2:8=-6_++ 3*LF\J,G[I-=#!^S/X
MS?X80^,(=.AN-%ELQ?!H9PTPA(SNV=>!R0.U>/+A[,)5)T51DY05Y*SNEW:-
MH\QS,,^,?Y)JS'/M!Y/&<D=^*R+:ZWJ#NRK<Y%78KC'\6>/Z5\W4IFT97.AY
M_OK_ -\T55\]O445G[,UYV=)_P %G_CE(NH>$_AS9S8C:)M=U55[X;R[:,_5
MA(V/^F8]:^'X+D8Y/_UZ[W]NSXB/\2/VS?B1?O(SQV>L/HT )X2.S5;? ]!Y
MB2'CNQKS2"ZXZ]><>M?TAQ1B'BLPJU'LG9>BT/C,=B'4Q,G\ON/T^_X(YN)/
MV5M2;;R/$]\,^^(O_P!5:'[=/["EI\?;&;Q5X4CM;7QI;IEE#!8=91>B.1P)
M!T#_ (&LO_@C-)YG[*>H'[W_ !5-_P#RBKQG]F7_ (*!77P!^,WBCPIXLFN+
M[P1<>(KU8)F)DDT-FN'Y7/)@).2O\.21W%??>VP"R?"X3,%[E2-K_P K25GY
M>I]%"I26&IPJ[21X#X&^%WB3XA?$F/P?I.D7$GB:25H)+.8&,VA4_.\Q(^1$
MZEC[8SD5^F_[*'[*&B?LM^$51'AU#Q'J"JNHZHZ[6G?KY48/W8QV4<G&3S70
M^*/%'@'X1Z'JWQ*O/[#T^WU"UB:[UJ&)3-J40'[I Z\R$YPJC-?(?PF_:_UK
M]JG]O;P6TGG:7X6T^>Z.EZ26^[^X<":;'#2D=N0@) [D\.6Y1EO#^)A[27M*
MU624?*+=K^7K]Q5&C2PTDF[R>WH=)_P5ND UCP#C^**]./QBKU;_ ()H_O/V
M4[%L<MJ%V3QU(>O(_P#@KW+Y.M?#_IS%>]?K%7K'_!,J0/\ LG:>V=W_ !,K
MO_T.HR^/_&:8B2_D_2!I3_WN7I_D>>7W_!56ZLM3NK4>"[=_LMQ) #_:!^;8
MY7/W>^*5/^"JMTX_Y$NVY]-1/_Q->M7/AC]GE[N9IM+^$YN/,8S%[2TW;]QW
M9XZYSGWKB?VC- ^"=G\"?%,GAK3_ (;PZY'8L;-["VMEN4DR/N%1N!^E98Z/
M$-&G.M',J?NINUHWTUM^AH_:J[YT>"_M(?M1ZA^TA?:<]QIL.DV>DH_E01N9
M69VZL6^@QBOK_P"$IW?L0Z0W]WPH?_1#5^<EO-B%O]WD_A7Z,_"+G]AC2&Z_
M\4G_ .T#7R/AYF&)QV88[%8N7-.5)W?_  "<+4E*3<CX'TB?=I]MZ>4O_H(K
M1BN,CZ]?>L'2)P=.M^0/W:Y[_P (K2BG^4_TK\)JT[-IF<9=CHO/7_:_,T55
M\Q?[R?E16?LT:>T/D7Q=K[^(_'.OZLQW/K&KWVHM[_:+J6;_ -G_ $J*WN./
M7GM2>(M*;P_XEU;39!B32]1NK!QZ/!/)"WZH:K#<JY'3O[5^\5HN;?-N?!\S
MNW(_4W_@BT_F?LG:B3\W_%4W_P#**OSW^*DN/C!XQ]?[>OA]?](>NT_9C_X*
M(^,/V3_AY-X9\/67AV>QFU";4I'OD=I0\NT$<,!CY>*\EU[QBWB?7=6UB;R?
MM&I74U],D7"J\C%V '89)QFO6SS,*&(RW#86G?FI[W7E;<]C$8R$\/3IQWBM
M3<;7[Z[TFWT^;4+Z:PM6+V]M)<.T$+>JH3A3]!7M7_!.J;=^V=X)'J]U_P"D
M[UY+\7O  ^#OBZWTF;4H[]KC3+/4_-$7DA1<1"39MR?NYQG//7 JW\%?C!J'
MP1^(^E^+-'2TFU#2O,:$7(+0G>A4[L>Q[&OF\+?"YA2JXF_N23?79IZ$T*CI
MUE[3[+/LG_@L-)Y>L_#WH!Y5[U^L5>N?\$O#O_9(T_WU&\'3_;KX+_:%_:^\
M1?M4W>CR>(H])A?15E%N+)"FX2;=V<DY^Z.E=1^SG^WMXN_9J\(SZ#I<.CZA
MIDDYN8XK]6W6[/\ >VE2#ANN#7U.'XFP-+B*KF,[^SE&U[:[1Z;]#UH8ZFL2
MZO1H]'U7_@E[\2KW7+ZXC_X1$+<7<TR WC[@K2%AGY.N#1#_ ,$O_B9$X^?P
MFN/2\?\ ^(IZ_P#!7+QT&^;0_"2M[B7_ .*J9/\ @K1XX= QT7PGACP<2\_^
M/5YU:CP7.3E-U+OUZ_(VYL&WNSS?XU_L_P#BC]GK5+:S\206R_;XFDMY[67S
M(9<?>&< @CC@BONKX.OG]A+1R>_A$G_R :^'?V@OVMM<_:;M])&M6.DV::.T
MC1&SW#?O !W;B>F*Z[X<_M^:_P"#_@Q%X';2](U*TALGTZ&[>1XYEA92H! X
M8J#@'O@9KAX?SC)LKS'%NC*7L9TW&+:;=]'9Z77DRJ%6G";MLUH>2Z+/_P 2
MVW[YB7_T$5II-N#8SP./KTK"L#]GMXXP2P10N?7 JX][]FM9)&/$<;.<GT4F
MOQVK3UL9QD=-YZ?Y-%=E_P ,^ZI_SQD_[X-%=7]DUNQM[1GRW^VGX*D^'?[8
M'Q.TF1-B_P#"1W6H1+C'[N[87:_A^_-><+_J/P-?;/\ P6T^"DFA?$SPK\0K
M2 BSURS.BZE(!PMQ$=]NQ_WHVD7_ ( HKXEQ^XK]RSS!O#8^I2?>Z]'J?)YA
M1=+$2B^]_OU/9O /Q"M_A5^QY9ZM8Z+I%SXNO?'^HV.G:M>VJ7#:3 NEV$DK
MHC@JTA.T)N!"!Y& R:MZIXPE_:+_ &8/'&K>(K739/%/P_\ LUY:ZQ;64=I-
M=VTS^5);S^6 LF"0RL1D8-5O!'B3PO8_L4V>B^+M-U.73=:^(NI/!JNEE6U#
M0KB'2=/*2QQOA)HW#LDD992588(*USOC7XF>%_#GP;U'P+X#77[RV\0W,=WK
MFN:U"EK/>>5GR;>*W1F$<2D[F+,2Q Z5U5Y)4X\TURNFER];N*MI;776YU2G
MRQ5Y+EY5IUO;3_ASU[]IW]HG6OA=XUT33_"\.C:3<1^%=*FOKU].BNKC4W-J
MI"R-*&Q&JX 1< \DU#XGT6Q@_:Y\.W6D^ U\22>(_#FG^)$\,605+5[^YL1*
MV58[5MTD_>,I(4#(R!7CGQZ^*=K\8O'%OJEC;W%I##HMCIC)<8W&2" 1LPQ_
M"2,COBO0=-_:?T4_$J.\N]*U63P_J?@"T\":LL#K'>QK';K$]Q;D_*3O0$*W
MWER#C-<M7%4JM::JSTYXN+MM:]]+6[7Z=7<V^LQE5:G+2ZL>KZ!H7B[QKX6\
M96'Q#UCX::G:Q>';R_M-.TZ[L9M1L+J$!T>$6H_=JG(8,V,<<FN6T+XF#X4_
MLD>!=2TG2-%;Q-KFK:O;C5;JQ2XEMK=!"750PQN;< &.=H!QUKF?A-\1OA7\
M%]3U.'3XO&VNQ^(-*N-&N=6N;*WLY-)AE3&;>U5V\V0D $LZC;D <UR^M_$:
MTU;X+>#_  K##="X\,ZCJ=U)/* $N([DQ>7@ \,!'\PZ G S7'C,53A2YXR7
M.HR6_,[\T6M;=KV-WB(QC=/6S6]WNOT/4+;XC2?"[]F;X?7FBV.DP^(M8O=7
M$NK2V<<]Q#!'.G[M-X*@LS'+$$@  5O?$_XTWWA'P+\/]>T?3]!TWQ1XUT2:
M_P!:U2'3(C)=-;W+01[$8%(]X^9RJ@L0*\:\0_$.WUWX4^"_#L<,\=QX8DU!
M[B5L;)1<RJZ[._RA3G-7O'WQ$MO&O@GP%I=O#<0S>$]&N=,N&DQMG>6Z,P9/
M8 XY[UX];,7&G.%.?V(*-OYE:[6F^]V:1Q.C2?1??I?]3UWQ%86\_P ?_!^H
MP>$?^$FO/$&@6^KOH=BBQ0W-\R. [)C:(0RAW7@=>0*Z_P .Z1XI\9V'B32_
M'FK?#V[LIM"U"XATZRN;.2_L[F"!IHGMQ;C,91D^;<V"H(()QGS#2_VC-+C\
M5Z7+<:;J3:0W@\>$M4$,BQW04[MTT!Z<9'RM]X9%6/A9X[^&WP?\13/8P>+-
M>CU33;O2I]1N+2&S?2HIX'C+06ZLWG2%BH)9U 0M@$FML/B,'[7G=1<KD^97
MLK-1W5KROKU27D==.M"^^E]=;?IJ<%IU[Y]K%(6 ,B*Q^I&:U]'T>;Q9J=IH
M]NIDN-8N(K"-5&26E<1_^S9_"N?B,=NYCA:22&(E(FE4+(Z#A2P!(#$8) )P
M<CFO?/\ @GA\-)/B'^T59ZE)&S:;X1A?4)6(X,Y&R!/U=O\ @ ]:^'RG*IXW
M,*6#C]J27ROJ_NNS*@N::B?H)_P@>G_\\5_*BM#RQ_>:BOZJ_P!7<K_Y]H]W
MF78\Y_:O_9_L_P!ICX#:UX1NOW<UY");*?O;W*?-$_Y@#Z&OQ-\2>&M1\%^(
MK_1]7MY+/5-+G:UNX'&"DBG!Q['J#W!K]_C ,?2OA7_@JS^PE-\0[.;XG>#[
M%YM>T^'&N6$"_-J%N@_UZCO)&!R!RR]B17E<6Y++$TEB:*O..Z[K_@'BYU@'
M6C[6GO'\4?G:VMWT_AJWT=KJ0Z7;7LNHQ6W\"7$L<<4D@_VFCBC7Z**I?9_>
MHXI Z*R_=/2IXCE!7Y9*3>Y\@[]1N&BQCFK%K<<=O\:CJ,JT7?C/ITS6<H*2
ML.+L:UM<<_>'^-7K:XSWY[@UAV]SD?4= ?U%7[:YSMY89]/\]:\^M2[FT)=S
M;AFS[]N15R"YVD#H.@K&MYRPSSSZG&*NPW )7^]ZXZUYM2ET.B$S:MI\K]*N
M6]Q\PY';FL6VN,+@<'TSWJY#<9&?;/L*\^K3MN=4)ZFY!,3M6-6D=F"HBC+.
M3P /<FOTY_8:_9_;X%_!>UCOH0NN:XPOM1/>-B/DC_X"N!^=?-G_  3@_9 F
M\9ZO9_$+Q-9R1Z+9OYFC6LJ_\?TH.//(Z^6ISC(&3ST%??=NF W?)S7[#X<\
M*RPZ>9XI6E)6@GND^OSZ>1]!E]!Q7M)==A_E#W_.BG45^MGH\J"HVMP3G)J2
MB@9\"_M]_P#!*\^,[_4/&WPPM(;?5;@F?4?#ZXCAOGZO-;]DD/4I]UMO&">?
MSQU+3+K0M6N+"^M;FPOK1BD]M<1F.:%NX93R*_H":TSWKQS]IC]B'X?_ +4U
MD6\0:5]GUJ,%(-7LL17D/IEA]X>S9KXG/.$8XF3KX6T9=5T?^3_ \+,,EC5;
MJ4=)?@S\78GXQWISKN7%?5?QS_X([_$WX<7,MUX/FT_Q[I(R0B2BSU*,>GEO
MB.3ZJZG_ &37S'X^\$Z_\*-0DM?%6A:YX9N(SAEU2PEME_!V78P/J&/6OSS%
MY7B\*^6O3:^6GWH^8K82M1=JD69I'E$58M[C+<GW-9MGK5K??ZF[MKCG_EG,
MK?R-.GU"#3OFFN((%[F20)_.O.G%-:F!O6T^<=V/.?6KUM/G S^':LOP7:7O
MCW48[3P_8:AXBNI& 6'2K22\9CV_U:L!^.!7TQ\$?^"6/Q:^*-Q!-K&GVG@7
M26P7FU6027A'^S;QYY_WW7Z&BCD^*Q,N6A3<ODSMP]&K5TA%L\)MIM[QJJ[Y
M)&"(B@LSMV  Y)/M7V5^Q3_P37O_ !G<V?BCXC6<FGZ*I$MKHCY6>_'9INZ1
MYP=O4XYP#7TA^S-_P3S\ _LY-#J$=M)XA\2)P=4U%0[H>_EI]U/PY]Z]\6W&
M/KUK[[A_@&%&:Q&86E):J/1>O?TV/I,'E?):=;5]B'3]/AM+*.&&*.&&%0D<
M<:A5C4# 4 <  =A5A(_+S0B>6*=7Z6DEL>T%%%%, HHHH *JO_#]?\***SGT
M 4?\L_J:B\1_\@*X_P"N9_E1166*_P!W?HR*W\+Y'Y1?M_\ _(S7'^^?ZUQ7
M[%W_ ".T'_71?YT45^&2_P!Z7J? 1_C/Y'Z__"__ )$ZT_W!6S+U_P"!445^
HWY;_ +O3]#[S"_PEZ!;_ 'OP-3I]VBBNU[FD?A0M%%%!04444 ?_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
